Drug Pricing & Out-of-Pocket

In Standard-Risk Myeloma, Two Years of Maintenance Equals Indefinite Therapy

In Standard-Risk Myeloma, Two Years of Maintenance Equals Indefinite Therapy

George Padron
Oncology Care, Hematologic Malignancies, Access & Affordability, Drug Pricing & Out-of-Pocket, Managed Care, Value Based Care | Jul 23, 2026
In standard-risk myeloma without an up-front transplant, stopping lenalidomide maintenance at 2 years matched indefinite therapy on survival, with fewer harms.
Load More
Only Healthcare Today Covering Clinical Healthcare, Access and Cost

Only Healthcare Today
Covering Clinical Healthcare, Access and Cost

1 Hewitt Square, Suite 139
East Northport, NY 11731

Who We Are


About Us Editorial Policy Contributors & Partners

Connect


Contact Us Work With Us Advertising Terms of Use Privacy Policy